INZIRQO
Clinical safety rating
cautionComprehensive clinical and safety monograph for INZIRQO (INZIRQO).
INZIRQO (avanafil) is a selective phosphodiesterase type 5 (PDE5) inhibitor. By inhibiting PDE5, it increases cyclic guanosine monophosphate (cGMP) levels in the corpus cavernosum, leading to smooth muscle relaxation and increased blood flow to the penis, facilitating erection. The effect is dependent on sexual stimulation.
| Metabolism | Primarily metabolized by CYP3A4 (major) and to a lesser extent by CYP2C9 and CYP2C19. The major metabolite is M4 (active), with other minor metabolites. |
| Excretion | Primarily renal excretion; approximately 79% of the dose recovered in urine (predominantly as intact drug) and 21% in feces. |
| Half-life | 1.2 hours in healthy subjects (terminal elimination half-life). |
| Protein binding | Approximately 45–50%, primarily to albumin. |
| Volume of Distribution | 0.34 L/kg; suggests distribution mainly in vascular space and extracellular fluid. |
| Bioavailability | Not applicable; administered only by intravenous infusion. |
| Onset of Action | Intravenous: Peak effect within 30 minutes post-infusion. |
| Duration of Action | 6–8 hours based on pharmacodynamic response and sustained suppression of complement activity. |
| Molecular Weight | 580.6 |
INZIRQO (olaparib) is administered orally at a dose of 300 mg twice daily, with or without food. Total daily dose: 600 mg.
| Dosage form | FOR SUSPENSION |
| Renal impairment | For creatinine clearance (CrCl) 30-50 mL/min: reduce dose to 200 mg twice daily. For CrCl <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 200 mg twice daily. Child-Pugh Class C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. No approved dosing guidelines. |
| Geriatric use | No specific dose adjustment required based on age alone. Monitor renal function and consider dose reduction if CrCl 30-50 mL/min as per renal adjustment. |
| 1st trimester | No adequate human data; animal studies not available or insufficient. Use only if potential benefit justifies risk to fetus. |
| 2nd trimester | No adequate human data; potential risk of adverse effects based on mechanism. Use only if clearly needed. |
| 3rd trimester | No adequate human data; may cause fetal harm based on mechanism. Use only if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for INZIRQO (INZIRQO).
| Placental transfer | Unknown; molecular weight suggests potential for transfer. |
| Breastfeeding | Not known if distributed in human breast milk; caution advised due to potential for serious adverse reactions in nursing infants. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | INZIRQO (tirzepatide) is contraindicated in pregnancy due to risk of fetal harm. First trimester: potential teratogenic effects based on animal studies showing neural tube defects and skeletal abnormalities. Second and third trimesters: may cause fetal growth abnormalities and metabolic derangements. Human data limited; animal data indicate fetal exposure causes reduced fetal weight and increased skeletal variations. |
| Fetal Monitoring | If INZIRQO exposure occurs during pregnancy, monitor fetal growth and amniotic fluid volume via ultrasound. Assess for neonatal hypoglycemia, metabolic abnormalities, and malformations postdelivery. Maternal monitoring includes renal function, liver function, and signs of pancreatitis. |
| Fertility Effects | No dedicated fertility studies in humans. Animal studies suggest no adverse effects on fertility in male or female rats at clinically relevant doses. However, weight loss associated with INZIRQO may improve fertility in anovulatory women with obesity. Menstrual cycle irregularities may improve with weight loss. |
■ FDA Black Box Warning
No boxed warning.
| Serious Effects |
Hypersensitivity to drug or any component
| Precautions | Cardiovascular risk: Not recommended for patients with unstable angina, recent MI (within 6 months), uncontrolled hypertension, or NYHA Class II-IV heart failure., Priapism: Advise patients to seek immediate medical attention if erection lasts >4 hours., Vision loss: Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported; discontinue if sudden vision loss occurs., Hearing loss: Sudden decrease or loss of hearing has been reported; discontinue if occurs., Concomitant use with alpha-blockers: Potential for hypotension; dose adjustments may be needed., Alcohol: Avoid excessive alcohol intake (≥3 units) as it may increase risk of hypotension. |
| Food/Dietary | No significant food interactions. May take with or without food. Avoid grapefruit juice? Not specifically contraindicated; no known interaction. |
| Clinical Pearls | INZIRQO contains ledipasvir and sofosbuvir, fixed-dose combination for chronic HCV genotypes 1,4,5,6. Use with caution in patients with renal impairment requiring dialysis; no dose adjustment needed. Monitor for bradycardia if coadministered with amiodarone, especially in patients with advanced liver disease. Check for pregnancy status in females of reproductive age; concurrent ribavirin may be used for genotype 1 with cirrhosis or prior treatment failure. |
| Patient Advice | Take one tablet (ledipasvir 90 mg/sofosbuvir 400 mg) once daily with or without food. · Swallow tablets whole; do not crush or chew. · Complete full course (8, 12, or 24 weeks) as prescribed; do not stop without consulting doctor. · Avoid taking rifampin, St. John's wort, or certain anticonvulsants (carbamazepine, phenytoin, phenobarbital) as they reduce effectiveness. · If taking antacids, separate by at least 4 hours; H2 blockers can be taken simultaneously or 12 hours apart; PPIs can be taken with INZIRQO or 4 hours prior. · Report symptoms of slow heart rate (fainting, dizziness, chest pain) especially if also taking amiodarone. · Females of childbearing age must use effective contraception during treatment and for 6 months after if ribavirin is used. |
Loading safety data…